Ross L. Levine

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Table S4 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S5 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S9 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S8 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Table S5 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Table S1 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S6 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S7 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Table S2 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S2 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S4 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Table S3 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S3 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Supplementary Figure S1 from CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify <i>KDM3B</i> as a Genotype-specific Vulnerability in <i>IDH2</i>- and <i>TET2</i>-mutant Cells

  2026-06-17

• Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients

  Leukemia · 2026-04-13

• Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness

  Nature Aging · 2025-11-25 · 15 citations

• Supplementary Data 3 from Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

  2025-11-25

• The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia

  Blood Neoplasia · 2025-11-25 · 1 citations

• Supplementary Figures1 from Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

  2025-11-25

• Supplementary Table 1 from Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

  2025-11-25